Benign Prostatic Hypertrophy Pending FDA approval for benign prostatic hypertrophy (BPH) Mechanism of Action Stimulates caspase, tumor necrosis factor, and B-cell lymphoma pathways in prostate glandular epithelial cells causing loss of cell membrane integrity, mitochondrial metabolic arrest, NRA depletion, NDA lysis and aggregation, and cell fragmentation and loss No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print